DK305390D0 - 11beta-substituerede progesteronanaloger - Google Patents
11beta-substituerede progesteronanalogerInfo
- Publication number
- DK305390D0 DK305390D0 DK305390A DK305390A DK305390D0 DK 305390 D0 DK305390 D0 DK 305390D0 DK 305390 A DK305390 A DK 305390A DK 305390 A DK305390 A DK 305390A DK 305390 D0 DK305390 D0 DK 305390D0
- Authority
- DK
- Denmark
- Prior art keywords
- progesteron
- 11beta
- analogs
- substituted
- alkynyl
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 2
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 abstract 1
- MAUMSNABMVEOGP-UHFFFAOYSA-N (methyl-$l^{2}-azanyl)methane Chemical compound C[N]C MAUMSNABMVEOGP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- -1 R4 is H Chemical group 0.000 abstract 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0052—Nitrogen only at position 16(17)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Control Of Eletrric Generators (AREA)
- Devices For Supply Of Signal Current (AREA)
- Sub-Exchange Stations And Push- Button Telephones (AREA)
- Light Receiving Elements (AREA)
- Led Devices (AREA)
- Junction Field-Effect Transistors (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Seasonings (AREA)
- Manufacture Of Tobacco Products (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/210,503 US4954490A (en) | 1988-06-23 | 1988-06-23 | 11 β-substituted progesterone analogs |
| US21050388 | 1988-06-23 | ||
| PCT/US1989/002706 WO1989012448A1 (en) | 1988-06-23 | 1989-06-23 | 11beta-SUBSTITUTED PROGESTERONE ANALOGS |
| US8902706 | 1989-06-23 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK305390A DK305390A (da) | 1990-12-21 |
| DK305390D0 true DK305390D0 (da) | 1990-12-21 |
| DK175760B1 DK175760B1 (da) | 2005-02-14 |
Family
ID=22783162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK199003053A DK175760B1 (da) | 1988-06-23 | 1990-12-21 | 11beta-substituerede progesteronanaloger |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US4954490A (da) |
| EP (1) | EP0422100B1 (da) |
| JP (1) | JP2953725B2 (da) |
| KR (1) | KR0161975B1 (da) |
| AT (1) | ATE149839T1 (da) |
| AU (1) | AU635211B2 (da) |
| CA (1) | CA1338906C (da) |
| DE (2) | DE68927861T2 (da) |
| DK (1) | DK175760B1 (da) |
| LU (1) | LU91575I2 (da) |
| NL (1) | NL300392I2 (da) |
| NO (2) | NO178264C (da) |
| WO (1) | WO1989012448A1 (da) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3832303A1 (de) * | 1988-09-20 | 1990-04-12 | Schering Ag | 11ss-phenyl-14ssh-steroide |
| DK0411733T3 (da) * | 1989-08-04 | 1999-06-28 | Schering Ag | 11-beta-aryl-gona-4,9-dien-3-oner |
| USRE34578E (en) * | 1990-05-07 | 1994-04-05 | Lubkin; Virginia | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| DE4042004A1 (de) * | 1990-12-22 | 1992-06-25 | Schering Ag | 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene |
| US5407928A (en) * | 1990-08-15 | 1995-04-18 | Schering Aktiengesellschaft | 11β-aryl-gona-4,9-dien-3-ones |
| JPH07508716A (ja) * | 1992-04-21 | 1995-09-28 | ザ スキーペンズ アイ リサーチ インスティテュート，インコーポレイテッド | シェーグレン症候群における眼のアンドロゲン療法 |
| US5536725A (en) * | 1993-08-25 | 1996-07-16 | Fmc Corporation | Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines |
| US5639598A (en) * | 1994-05-19 | 1997-06-17 | The Trustees Of The University Of Pennsylvania | Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions |
| US5780220A (en) * | 1994-05-19 | 1998-07-14 | Trustees Of The University Of Pennsylvania | Methods and compositions for inhibiting HIV replication |
| DK0683172T3 (da) * | 1994-05-19 | 1998-03-30 | Akzo Nobel Nv | 11,21-bisphenyl-19-norpregnanderivater |
| US5929262A (en) * | 1995-03-30 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates |
| US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| ES2152671T3 (es) * | 1996-05-01 | 2001-02-01 | Us Gov Health & Human Serv | Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales. |
| WO1998005679A2 (en) * | 1996-08-05 | 1998-02-12 | Duke University | Mixed agonists of the progesterone receptor and assays therefor |
| US6090798A (en) * | 1997-12-19 | 2000-07-18 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with glucocorticoid antagonists |
| US6020328A (en) * | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| US5962444A (en) * | 1998-05-29 | 1999-10-05 | Research Triangle Institute | 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| US6262042B1 (en) | 1998-05-29 | 2001-07-17 | Research Triangle Institute | 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| US6172052B1 (en) * | 1998-12-04 | 2001-01-09 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
| ATE396197T1 (de) * | 2000-03-17 | 2008-06-15 | Us Gov Health & Human Serv | 17-alpha-substituierte-11-beta-substituierte-4- aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität |
| DE60233111D1 (de) * | 2001-02-14 | 2009-09-10 | Karobio Ab | Glucocorticoid-rezeptoren-modulatoren |
| ES2212912B1 (es) * | 2003-01-22 | 2005-10-01 | Crystal Pharma, S.A. | Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona. |
| AU2004217988C1 (en) | 2003-02-28 | 2010-06-03 | Southwest Foundation For Biomedical Research | Method for preparing 17 alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates |
| US20060247452A1 (en) * | 2004-01-21 | 2006-11-02 | Guisasola Luis Octavio S | Method for obtaining 17sg(a)-acetoxy-11$g(b)-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione |
| JP5017109B2 (ja) * | 2004-07-09 | 2012-09-05 | ザ・ポピュレイション・カウンシル，インコーポレイテッド | プロゲステロン受容体モジュレーターを含有する徐放性組成物 |
| EP1862468A1 (de) * | 2006-06-02 | 2007-12-05 | Bayer Schering Pharma Aktiengesellschaft | Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on |
| HU227112B1 (hu) * | 2006-06-14 | 2010-07-28 | Richter Gedeon Nyrt | Ipari eljárás 17-alfa-acetoxi-11-béta-[4-(N,N-dimetil-amino)-fenil]-19-norpregna-4,9-dién-3,20-dion elõállítására és új intermedierek az eljáráshoz |
| SI2148681T1 (sl) * | 2007-04-20 | 2016-07-29 | Preglem S.A. | Selektivni modulatorji progesterona v zdravljenju maternične krvavitve |
| HU228636B1 (en) * | 2007-06-27 | 2013-04-29 | Richter Gedeon Nyrt | Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process |
| EP2532350A1 (en) | 2007-10-17 | 2012-12-12 | Laboratoire HRA Pharma | Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome |
| US8299050B2 (en) | 2008-01-29 | 2012-10-30 | Laboratoire Hra-Pharma | Method for treating uterine fibroids |
| US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
| WO2010119029A1 (en) | 2009-04-14 | 2010-10-21 | Laboratoire Hra-Pharma | Method for on-demand contraception |
| DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034362A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034525A1 (de) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| US8426392B2 (en) | 2009-12-09 | 2013-04-23 | Laboratoire Hra-Pharma | Method for providing emergency contraception |
| WO2011091890A1 (en) | 2010-02-01 | 2011-08-04 | Laboratoire Hra-Pharma | A method for post coital contraception in overweight for obese female subjects using ulipristal acetate |
| US20130045959A1 (en) | 2010-02-01 | 2013-02-21 | Andre Ulmann | Method for late post coital contraception using ulipristal acetate |
| DE102010007719A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| MX2012010327A (es) * | 2010-03-22 | 2012-11-16 | Repros Therapeutics Inc | Composiciones y metodos para la administracion no toxica de antiprogestinas. |
| WO2011150209A1 (en) | 2010-05-26 | 2011-12-01 | Corcept Therapeutics, Inc. | Treatment of muscular dystrophy |
| CN102372760A (zh) * | 2010-08-12 | 2012-03-14 | 杭州容立医药科技有限公司 | 一种合成孕酮受体调节剂优力司特的合成方法 |
| UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| EP2471537A1 (en) | 2010-12-30 | 2012-07-04 | PregLem S.A. | Treatment of pain associated with dislocation of basal endometrium |
| CN102516345B (zh) | 2011-11-01 | 2014-11-26 | 上海优拓医药科技有限公司 | 醋酸乌利司他及其关键中间体的制备方法 |
| EP2545922A1 (en) | 2011-07-12 | 2013-01-16 | PregLem S.A. | Treatment of excessive menstrual bleeding associated with uterine fibroids |
| CN102321141B (zh) * | 2011-07-22 | 2013-05-15 | 上海希迈医药科技有限公司 | 一种17α-乙酰氧基-11β-（4-N,N-二甲氨基苯基）-19-去甲孕甾-4，9-二烯-3,20-二酮的无定形物及其制备方法 |
| CN102344478B (zh) * | 2011-07-22 | 2013-08-07 | 上海希迈医药科技有限公司 | 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法 |
| CN104628806A (zh) * | 2012-01-19 | 2015-05-20 | 华润紫竹药业有限公司 | 甾体化合物及其制备方法和用途 |
| CN106046099B (zh) * | 2012-01-19 | 2018-03-16 | 华润紫竹药业有限公司 | 甾体化合物及其制备方法和用途 |
| FR2987271B1 (fr) | 2012-02-28 | 2017-08-18 | Hra Pharma Lab | Combinaison de modulateurs selectifs du recepteur a la progesterone et d'anti-inflammatoires non steroidiens |
| EP2641602A1 (en) | 2012-03-23 | 2013-09-25 | PregLem S.A. | Method for treating gynecological diseases |
| CN102675395B (zh) * | 2012-04-17 | 2014-04-30 | 常州市第四制药厂有限公司 | 醋酸乌利司他的多晶型及其制备方法 |
| HUE037889T2 (hu) | 2012-05-25 | 2018-09-28 | Hra Pharma Lab | Ulipristal acetát melltumorok megelõzésére és kezelésére |
| CA2872644A1 (en) | 2012-05-31 | 2013-12-05 | Allergan Pharmaceuticals International Limited | Formulations and methods for vaginal delivery of antiprogestins |
| CN102702296B (zh) * | 2012-06-19 | 2014-09-03 | 山东诚创医药技术开发有限公司 | 环-3,20-双(1,2-亚乙基缩醛)-17α-羟基-17β-乙酰基-雌甾-5(10),9(11)-二烯-3-酮的制备方法 |
| JP6474722B2 (ja) | 2012-09-28 | 2019-02-27 | あすか製薬株式会社 | ウリプリスタール酢酸エステルの結晶多形 |
| WO2014050107A1 (en) | 2012-09-28 | 2014-04-03 | Aska Pharmaceutical Co., Ltd. | Crystalline polymorphic form of ulipristal acetate |
| JP6200493B2 (ja) | 2012-09-28 | 2017-09-20 | あすか製薬株式会社 | 無定形ウリプリスタール酢酸エステル |
| WO2014060888A1 (en) | 2012-10-18 | 2014-04-24 | Lupin Limited | Novel process and intermediate for preparation of ulipristal |
| CN103772468B (zh) * | 2012-10-19 | 2017-04-05 | 华润紫竹药业有限公司 | 醋酸特拉司酮及其中间体的制备方法和用途 |
| US9545411B2 (en) | 2012-11-02 | 2017-01-17 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
| FR2997628B1 (fr) * | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone |
| FR2997627B1 (fr) * | 2012-11-08 | 2015-01-16 | Hra Pharma Lab | Produit de co-micronisation comprenant de l'ulipristal acetate |
| FR2999081B1 (fr) | 2012-12-06 | 2015-02-27 | Hra Pharma Lab | Dispersion solide d'un modulateur selectif du recepteur a la progesterone |
| CN103073612B (zh) * | 2013-02-04 | 2015-11-04 | 山东大学 | 醋酸乌利司他关键中间体的制备方法 |
| KR20150139919A (ko) | 2013-04-10 | 2015-12-14 | 쁘레글렘 에스아 | 자궁 섬유종의 치료에서 사용하기 위한 프로게스테론 수용체 조절제 |
| HU230319B1 (hu) * | 2013-10-01 | 2016-01-28 | Richter Gedeon Nyrt. | Ipari eljárás szteroid hatóanyagok előállítására |
| JP6821582B2 (ja) | 2015-03-02 | 2021-01-27 | コーセプト セラピューティクス， インコーポレイテッド | Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用 |
| JP6754533B2 (ja) | 2015-03-30 | 2020-09-16 | コーセプト セラピューティクス， インコーポレイテッド | 副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用 |
| MX383318B (es) | 2015-08-13 | 2025-03-13 | Corcept Therapeutics Inc | Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina. |
| JP6765443B2 (ja) | 2016-01-19 | 2020-10-07 | コーセプト セラピューティクス， インコーポレイテッド | 異所性クッシング症候群の鑑別診断 |
| CN105669810B (zh) * | 2016-02-19 | 2017-05-10 | 常州市第四制药厂有限公司 | 一种醋酸乌利司他的杂质及其制备和检测方法 |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| FR3060389B1 (fr) | 2016-12-20 | 2019-05-31 | Laboratoire Hra-Pharma | Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites |
| AU2018244928B2 (en) | 2017-03-31 | 2023-10-19 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| WO2018236749A2 (en) | 2017-06-20 | 2018-12-27 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| WO2017216637A2 (en) | 2017-08-04 | 2017-12-21 | Alvogen Malta Operations (Row) Ltd | Tablet form including ulipristal acetate and the methods for its preparation |
| CN109053846B (zh) * | 2018-08-14 | 2020-01-07 | 台州仙琚药业有限公司 | 制备醋酸优力司特双缩酮的方法 |
| AU2020239920A1 (en) * | 2019-03-18 | 2021-11-04 | Arnold L. Newman | Method of improving insulin sensitivity |
| EP3895692A1 (en) | 2020-04-15 | 2021-10-20 | LTS Lohmann Therapie-Systeme AG | Oral thin film with smooth fused film |
| EP3895691A1 (en) | 2020-04-15 | 2021-10-20 | LTS Lohmann Therapie-Systeme AG | Ulipristal acetate otf |
| EP4263807A2 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Processing of tumor infiltrating lymphocytes |
| EP4151204A1 (de) | 2021-09-17 | 2023-03-22 | LTS Lohmann Therapie-Systeme AG | Schnell zerfallende orale dünne filme/schäume mit hoher wirkstoffbeladung auf basis eines gemisches von polyvinylalkoholen mit unterschiedlichen molekulargewichten |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2377418A1 (fr) * | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
| ZA8231B (en) * | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
| FR2522328B1 (fr) * | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| ES8502612A1 (es) * | 1983-06-15 | 1985-02-01 | Schering Ag | Procedimiento para la preparacion de 13a-alquilgonanos |
| FR2586021B1 (fr) * | 1985-08-09 | 1988-10-14 | Roussel Uclaf | Nouveaux produits derives de la structure 5a-oh d 9(10) 19-nor steroides |
| IE60780B1 (en) * | 1987-01-23 | 1994-08-10 | Akzo Nv | New 11-aryl steroid derivatives |
-
1988
- 1988-06-23 US US07/210,503 patent/US4954490A/en not_active Expired - Lifetime
-
1989
- 1989-06-22 CA CA000603686A patent/CA1338906C/en not_active Expired - Lifetime
- 1989-06-23 JP JP1507392A patent/JP2953725B2/ja not_active Expired - Fee Related
- 1989-06-23 EP EP89907924A patent/EP0422100B1/en not_active Expired - Lifetime
- 1989-06-23 DE DE68927861T patent/DE68927861T2/de not_active Expired - Lifetime
- 1989-06-23 AU AU38506/89A patent/AU635211B2/en not_active Expired
- 1989-06-23 AT AT89907924T patent/ATE149839T1/de active
- 1989-06-23 DE DE122009000031C patent/DE122009000031I2/de active Active
- 1989-06-23 WO PCT/US1989/002706 patent/WO1989012448A1/en not_active Ceased
- 1989-06-23 KR KR1019900700406A patent/KR0161975B1/ko not_active Expired - Lifetime
-
1990
- 1990-04-03 US US07/504,129 patent/US5073548A/en not_active Expired - Lifetime
- 1990-12-21 DK DK199003053A patent/DK175760B1/da active Protection Beyond IP Right Term
- 1990-12-21 NO NO905546A patent/NO178264C/no not_active IP Right Cessation
-
2009
- 2009-06-03 LU LU91575C patent/LU91575I2/fr unknown
- 2009-06-11 NL NL300392C patent/NL300392I2/nl unknown
- 2009-06-22 NO NO2009014C patent/NO2009014I2/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL300392I2 (nl) | 2009-10-01 |
| DK305390A (da) | 1990-12-21 |
| KR900701820A (ko) | 1990-12-04 |
| JPH03505582A (ja) | 1991-12-05 |
| ATE149839T1 (de) | 1997-03-15 |
| WO1989012448A1 (en) | 1989-12-28 |
| LU91575I2 (fr) | 2009-08-03 |
| DE68927861D1 (de) | 1997-04-17 |
| EP0422100B1 (en) | 1997-03-12 |
| EP0422100A1 (en) | 1991-04-17 |
| NL300392I1 (nl) | 2009-08-03 |
| US4954490A (en) | 1990-09-04 |
| JP2953725B2 (ja) | 1999-09-27 |
| DE122009000031I2 (de) | 2011-06-16 |
| DK175760B1 (da) | 2005-02-14 |
| CA1338906C (en) | 1997-02-11 |
| NO2009014I1 (no) | 2009-07-06 |
| NO178264C (no) | 1996-02-21 |
| NO178264B (no) | 1995-11-13 |
| US5073548A (en) | 1991-12-17 |
| AU3850689A (en) | 1990-01-12 |
| NO905546D0 (no) | 1990-12-21 |
| DE68927861T2 (de) | 1997-10-16 |
| EP0422100A4 (da) | 1994-04-27 |
| NO2009014I2 (no) | 2009-12-28 |
| AU635211B2 (en) | 1993-03-18 |
| DE122009000031I1 (de) | 2009-11-05 |
| NO905546L (no) | 1990-12-21 |
| KR0161975B1 (ko) | 1998-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK305390A (da) | 11beta-substituerede progesteronanaloger | |
| FI823923L (fi) | Antifibrinolytiskt aktiva foereningar | |
| SE7712891L (sv) | Nya spirolaktoner och sett att framstella densammma | |
| ES2158284T3 (es) | Metil-fenil-oxazolidinonas quirales. | |
| SE8103963L (sv) | 10-alkynyl-steroider | |
| RO77559A (ro) | Procedeu de preparare a eritro-9-(2-hidroxi-3-alchil)hidroxantinei | |
| DK0414610T3 (da) | Fremgangsmåde til enantioselektiv fremstilling af phenylisoserinderivater | |
| GR3005766T3 (da) | ||
| AR247744A1 (es) | Compuestos organosilano y catalizadores que contienen dichos compuestos | |
| AU8577282A (en) | Light-sensitive mixture and copying material prepared therefrom | |
| NO840037L (no) | Cykloalifatiske farmasoeytiske forbindelser | |
| GB8306412D0 (en) | Crown ether compounds | |
| TW215947B (da) | ||
| JPS5520735A (en) | Cosmetic | |
| SE8505766L (sv) | Rodiumkatalysator och anvendning derav | |
| IT1195967B (it) | Guarnizione di tenuta all'aria per statore di un compressore | |
| FI812777L (fi) | Foerfarande foer framstaellning av nya cardenolid-bis-digitoxosider | |
| SE8303091D0 (sv) | Analogues of neurohypophysial hormones with inhibition effects | |
| SE8103598L (sv) | Antiinflammatoriska medel for yttre anvendning | |
| JPS5321147A (en) | Methylated oxoprostaglandin analogs | |
| SU1333066A1 (ru) | Светочувствительное соединение в вакуумных фотолитографических процессах | |
| SE8302972L (sv) | Nya karbamidkompositioner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CTFF | Application for supplementary protection certificate (spc) filed |
Spc suppl protection certif: CA 2009 00018 Filing date: 20090617 Expiry date: 20140623 |
|
| PUP | Patent expired | ||
| CTFG | Supplementary protection certificate (spc) issued |
Free format text: PRODUCT NAME: ULIPRISTALACETAT Spc suppl protection certif: CA 2009 00018 Filing date: 20090617 |